FAST NEWS: HutchMed Shares Plunge on U.S. Cancer Drug Rejection
The latest: HutchMed (China) Ltd. (HCM.US; 0013.HK) announced late Monday that its Surufatinib drug for the treatment of advanced neuroendocrine tumors was denied approval by the U.S. Food and Drug…
Recent Articles
RELATED ARTICLES
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
Discover hidden China stock gems in our weekly newsletter